EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Penumbra's Enterprise Value is MXN211,166 Mil.
Penumbra's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was MXN3,871 Mil. Therefore, Penumbra's EV-to-FCF for today is 54.55.
The historical rank and industry rank for Penumbra's EV-to-FCF or its related term are showing as below:
MEX:PEN'
s EV-to-FCF Range Over the Past 10 Years
Min: -69927.64 Med: -6.94 Max: 26466.1
Current: 56.66
During the past 13 years, the highest EV-to-FCF of Penumbra was 26466.10. The lowest was -69927.64. And the median was -6.94.
MEX:PEN's EV-to-FCF is ranked worse than 80.14% of 418
companies
in the Medical Devices & Instruments industry
Industry Median: 22.765
vs MEX:PEN: 56.66
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Penumbra's share price for today is MXN4775.70.
Penumbra's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN79.749.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Penumbra EV-to-FCF Related Terms
Penumbra EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Penumbra's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Penumbra's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Penumbra EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Penumbra's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Penumbra's EV-to-FCF falls into.
Penumbra's current Enterprise Value is MXN211,166 Mil.
Penumbra's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN3,871 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Penumbra (MEX:PEN) has a EV-to-FCF of 54.55 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Penumbra and its competitors. According to the industry distribution chart, Penumbra ranks #335 out of 418 companies in the Medical Devices & Instruments industry, placing it in the top 80.1%.
Is Penumbra's EV-to-FCF too high?
Penumbra's current EV-to-FCF is 54.55. The Medical Devices & Instruments industry median EV-to-FCF is 22.77. Penumbra's value of 54.55 is 139.6% above this industry median. Based on the distribution chart, Penumbra ranks #335 out of 418 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Penumbra has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Penumbra's EV-to-FCF compare to GMED and PODD?
According to the Medical Devices & Instruments industry distribution chart, Penumbra ranks #335 out of 418 companies for EV-to-FCF. This places Penumbra in the lower half of its industry. The industry median EV-to-FCF is 22.77. Penumbra's value of 54.55 is 139.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.77, based on 418 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Penumbra's current EV-to-FCF of 54.55 is 139.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Penumbra and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Penumbra's current EV-to-FCF is 54.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Penumbra stock overvalued right now?
Penumbra (MEX:PEN) has a current EV-to-FCF of 54.55. The stock's GF Value™ is MXN4,994.10, compared to a current price of MXN4,775.70 — trading 4.4% below its estimated fair value. The current EV-to-FCF is 54.55 and 139.6% above the Medical Devices & Instruments industry median of 22.77. Penumbra's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Penumbra (MEX:PEN), the current EV-to-FCF is 54.55 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Penumbra (MEX:PEN) Overvalued in 2026?
Based on GuruFocus' analysis, Penumbra stock appears to be undervalued.
The current stock price of MXN4,775.70 is trading 4.4% below its estimated GF Value™ of MXN4,994.10.
Key valuation signals for MEX:PEN:
EV-to-FCF: 54.55
GF Value™: MXN4,994.10 vs. price of MXN4,775.70 (4.4% below fair value)
Industry Position: 139.6% above the Medical Devices & Instruments median (#335 of 418)
No single metric tells the full story. See the MEX:PEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
89GF Score
Get the complete analysis for MEX:PEN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PEN has been successfully added to your 
